Spark Therapeutics is using gene therapy to challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. The Company successfully applied its technology in the first gene therapy approved in both the U.S. and EU for a genetic disease. Spark currently has four programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia.